Press releases
26 September - 2023
Toleranzia starts toxicology study of its lead drug candidate TOL2
12 January - 2023
27 December - 2022
14 November - 2022
Flerie Invest AB has announced a mandatory bid to the shareholders of Toleranzia AB
3 June - 2022
Positive results for Toleranzia’s drug candidate TOL2 published in reputable scientific journal
10 May - 2022
Toleranzia attends international scientific conference on myasthenia gravis in the USA
9 May - 2022
28 March - 2022
Toleranzia secures access to materials for large-scale manufacturing of drug candidate TOL2
11 November - 2021
Toleranzia AB (publ) today announces that the planned start of a first clinical study of its...
10 November - 2021
Toleranzia appoints Ann-Charlotte Rosendahl as Chair of the Board
21 September - 2021
20 September - 2021
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR...
16 September - 2021
Bulletin from the extraordinary general meeting in Toleranzia AB (publ) on 16 September 2021
13 September - 2021
Today, 13 September 2021, is the last day for trading in warrants of series TO3 in...
30 August - 2021
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR...